Can intermediate monocytes predict response to infliximab therapy in sarcoidosis?

descriptionPublicationkeyboard_double_arrow_right Article 07 Jul 2016 English Publisher:European Respiratory Society (ERS)Journal:European Respiratory Journal, volume 48, pages 1,242-1,245 (issn: 0903-1936, eissn: 1399-3003,

Copyright policy )

Authors: Daniëlle, Hijdra; Adriane D M, Vorselaars; Heleen A, Crommelin; Coline H M, van Moorsel; Bob, Meek; Anke M E, Claessen; Ger T, Rijkers; +1 Authors

doi: 10.1183/13993003.00709-2016

pmid: 27390275

Can intermediate monocytes predict response to infliximab therapy in sarcoidosis?

- Summary
- Subjects
- Metrics

Abstract

Responders to infliximab therapy have more intermediate monocytes at baseline compared with non-responders http://ow.ly/fMLp300oVrO

Related Organizations

St. Antonius Ziekenhuis
Netherlands
University Medical Center Utrecht
Netherlands
University College Roosevelt
Netherlands

Keywords

Sarcoidosis, Receptors, IgG, Prognosis, Infliximab, Monocytes, Leukocyte Count, Fluorodeoxyglucose F18, Antirheumatic Agents, Case-Control Studies, Positron-Emission Tomography, Humans, Radiopharmaceuticals

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	16
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average